Salt Lake City-based Alzamend Neuro Inc. has announced that it has appointed biotechnology veteran Stephan Jackman as its CEO. Jackman has over 20 years of multi-industry experience in administration, business and product development, marketing, project and program management and strategic planning, according to a release from Alzamend.
Alzamend Neuro develops and markets immunotherapeutic treatment and vaccines for Alzheimer’s disease.
“The company believes (Jackman) will provide Alzamend a dynamic blend of bio-pharma experience and corporate leadership to navigate the challenges commonly faced by a developmental biotech company as it pursues the commercialization of its two therapeutic patented solutions for Alzheimer’s disease,” the statement from Alzamend said.
“I am committed to leading this visionary team of scientists and strategic partners to bring novel treatments to the 5.7 million Americans afflicted by this devastating disease,” said Jackman. “At Alzamend, we are very familiar with the emotional, physical and economic impact of Alzheimer’s, since a few of our team members are caregivers to loved ones living with the disease.”
Jackman has held leadership positions at Novartis Pharmaceuticals Corp., L’Oreal USA, SBM Management Services and Family Intervention Services. Prior to joining Alzamend Neuro, Jackman was the chief operating officer of Ennaid Therapeutics, a biopharmaceutical focusing on cures for mosquito-borne infectious diseases, such as Zika and Dengue viruses.
Milton Ault III, founder and executive chairman of Alzamend, said, “We are very excited about the appointment of Mr. Jackman as our CEO. Our company is committed to supporting the full product development life cycle of treatment and cures for Alzheimer’s disease and Alzamend is now at the doorstep of the next very important step, FDA registration and application to conduct human clinical trials.”
Jackman earned an M.S. in management and a B.S. in mechanical engineering from the Stevens Institute of Technology.